Temoside (Temozolomide) 250 mg
Temoside 250 (Temozolomide 250 mg) is an alkylating cytotoxic chemotherapy agent, the gold standard treatment for malignant brain tumors.
Manufacturer: Cipla (India). Temoside is a clinically proven generic equivalent of the brand name drug Temodar. Its key unique feature is its ability to easily cross the blood-brain barrier, which most other chemotherapy medications cannot do.
Mechanism of Action:
Temozolomide damages the DNA of cancer cells, preventing them from dividing and replicating, which leads to death of malignant cells.
β Key Benefit: Slows tumor growth, extends remission and improves overall survival for patients with brain cancer.
Main indications:
- π§ Glioblastoma multiforme: The most common type of malignant brain tumor in adults. Used in combination with radiation therapy first, then as maintenance monotherapy.
- π§ Anaplastic astrocytoma: For treatment of recurrent or progressive disease after prior therapy.
- May also be prescribed by an oncologist for treatment of other cancer types with brain metastases.
Dosage form: Pack of 5 capsules, 250 mg each.
β οΈ Administration guidelines:
- Dosage is calculated individually by your oncologist based on patient body weight and blood test results.
- π½οΈ Take STRICTLY ON AN EMPTY STOMACH, preferably shortly before bedtime to minimize nausea. Swallow capsules whole, do not crush or chew.
- π Standard treatment cycle: take Temozolomide for 5 consecutive days, followed by a 23 day break. The full 28-day cycle is repeated as prescribed by your doctor.
- π Anti-emetic (anti-nausea) medication is mandatory 30-60 minutes before each dose.
- Severe myelosuppression (low white blood cell or platelet count before starting treatment).
- Severe hepatic or renal impairment.
- Pregnancy and breastfeeding.
- Hypersensitivity to temozolomide.
Most common side effects:
- π€’ Nausea, vomiting, and bowel changes, which are well managed with anti-emetic drugs and usually resolve within the first days of the course.
- π Temporary decrease in white blood cell and platelet counts, requiring regular blood test monitoring.
- π΄ Fatigue, general weakness and headaches.
- Rare: temporary hair loss.
What Customers Say
No reviews yet
Your review can be the first!